The therapeutic value of poly(ethylene glycol)-modified proteins

Advanced Drug Delivery Reviews

Volumn 6, Issue 2, 1991, Pages 133-151

  Nucci, Mary L ^a   Shorr, Robert ^a   Abuchowski, Abraham ^a  

^a Enzon Incorporated   (United States)

Author keywords

Enzyme; Enzyme replacement; Enzyme therapy; Monomethoxypoly(ethylene glycol); Monomethoxypoly(ethylene glycol) modified; PEGNOLOGYSM; Protein modification; Protein therapy

Indexed keywords

BIOLOGICAL MATERIALS - BLOOD; DRUG PRODUCTS; ENZYMES; POLYMERS;

ANTICANCER ENZYMES; ENZYME REPLACEMENT THERAPY; HUMAN RECOMBINANT PROTEINS; PEGNOLOGY; POLY(ETHYLENE GLYCOL) MODIFICATION TECHNOLOGY; PROTEIN THERAPY;

PROTEINS;

ALFERON B; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALTEPLASE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH HORMONE; HEPATITIS B VACCINE; HUMAN GROWTH HORMONE; HUMAN INSULIN; INSULIN; MACROGOL DERIVATIVE; PROTEIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SOMATREM; SUPEROXIDE DISMUTASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

CANCER THERAPY; ENZYME REPLACEMENT; ENZYME THERAPY; ERYTHROCYTE; HUMAN; OXYGEN TOXICITY; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW;

EID: 0026124772     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(91)90037-D     Document Type: Review

References (138)

1. The absorption and excretion of the solid polyethylene glycols (‘Carbowax compounds’)
2. The toxicity of high molecular weight polyethylene glycols: chronic oral and parenteral administration
3. A study of the polyethylene glycols as vehicles for intramuscular and subcutaneous injections
4. The toxicology of the polyethylene glycols
5. Applications of polyethylene glycol-modified enzymes in biotechnological processes: organic solvent-soluble enzymes
6. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol
7. Laboratory synthesis of polyethylene glycol derivatives
8. A new procedure for the synthesis of polyethylene glcyol-protein adducts: effects on function, receptor recognition, and clearance of superoxide dismutase, lactoferrin and α2-macroglobulin
9. Cancer therapy with chemically modified enzymes
10. Reduction of immunogenicity and extension of circulating half-life of peptides and proteins
11. Modification of E. coli asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum
12. Some properties of polyethylene glycol:phenylalanine ammonia lyase adducts
13. Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol
14. Effects of coupling chemistry on the activity of polyethylene glycol modified alkaline phosphatase
15. Circular dichromism and fluorescence of polyethylene glycol-subtilisin in organic solvents
16. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase
17. Catalytic activity of administered gulonolactone oxidase polyethylene glcyol conjugates
18. Immunotherapy with momomethoxypolyethylene glycol modified allergens
19. Polyethylene glycols containing enzymatically degradable bonds
20. Properties of novel PEG derivative of calf adenosine deaminase
21. Preparation of polyethylene glycol tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species
22. Immunologic responses to conjugates of antigen E in patients with ragweed hay fever
23. Suppression of reaginic antibodies with modified allergens
24. Enzyme therapy
25. Improved modification of yeast uricase with polyethylene glycol accompanied with non-immunoreactivity towards anti-uricase serum and high enzymic activity
26. Synthesis and application of a poly(ethylene glycol)-antibody affinity ligand for cell separations in aqueous polymer two-phase systems
27. Structure activity relations in homologous alkyl polyglycol ethers
28. Suppression of reaginic antibodies with modified allergens
29. Modification of acyl-plasmin-streptokinase complex with polyethylene glycol
30. Preparation and properties of polyethylene glycol-trypsin adducts
31. Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol)
32. Soluble Polymer Enzyme Adducts
33. Chemical reactions by polyethylene glycol modified enzymes in chlorinated hydrocarbons
34. Modification of batroxobin with activated polyethylene glycol: reduction of binding ability towards anti-batroxobin antibody and retention of defibrinogenation activity in circulation of preimmunized dogs
35. Enzyme therapy
36. Modification of amino groups in porcine pancreatic elastase with polyethylene glycol in relation to binding ability towards anti-serum and to enzymic activity
37. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
38. Preparation of a polyethylene glycol-superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity
39. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol
40. Suppression of reaginic antibodies with modified allergens
41. Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxypolyethylene glycol modified allergens or placebo, and in healthy blood donors
42. Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase
43. Immune responses to polyethylene glycol modified l-asparaginase in mice
44. Immunogenicity of polyethylene glycol-modified superoxide dismutase and catalase
45. Suppression of reaginic antibodies with modified allergens
46. Reduction in immunogenicity and clearance rate of Escherichia coli l-asparginase by modifification with monomethoxypolyethylene glycol
47. Oxygen radical dependent lung damage following thermal injury of rat skin
48. Anti-inflammatory and pharmacokinetic properties of superoxide dismutase derivatized with polyethylene glycol via active esters
49. Hypouricemic effect of polyethylene glycol modified urate oxidase
50. Comparison of anaphylactic reactions to l-asparaginase derived from E. coli and Erwinia cultures
51. Anaphylaxis to l-asparaginase during treatment for acute lymphoblastic leukemia in children-evidence of a complement mediated mechanism
52. Hypersensitivity reactions and antibody formation during l-asparaginase treatment of children and adults with acute leukemia
53. Modified pharmacokinetics of l-asparaginase from E. coli by the formation of specific antibodies to l-asparaginase of different immunoglobulin classes in children with acute lymphoblastic leukemia
54. The effects of immunization to l-asparaginase on antitumor and enzymatic activity
55. l-Asparaginase
56. Clinical pharmacology of intramuscularly administered l-Asparaginase
57. Clinical pharmacologic studies of l-asparaginase
58. Biochemical and pharmacological studies with asparaginase in man
59. Asparaginase
60. Clinical experience with polyethylene glycol coupled E. coli asparaginase in patients with recurrent ALL
61. A phase II study of polyethyleneglycol (PEG) conjugated l-asparaginase in patients with refractory acute leukemias
62. A preliminary evaluation of asparaginase:polyethylene glycol conjugate against canine lymphosarcoma
63. l-asparaginase versus PEG-l-asparaginase in non-Hodgkin's lymphoma: a phase III trial in a canine model
64. A phase III trial of peg-l-asparaginase in the treatment of non-Hodgkin's lymphoma
65. Cancer therapy with chemically modified enzymes
66. Immunosuppressive properties and circulating life of Achromobacter glutaminase-asparaginase covlaently attached to polyethylene glycol in man
67. Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin's lymphoma
68. The clinical efficacy of poly(ethylene glycol)-modified proteins
69. Adenosine deaminase deficiency: frequency and comparative pathology in autosomally recessive severe combined immunodeficiency
70. Immune response to polyethylene glycol modified bovine adenosine deaminase (PEG-ADA)
71. Antigen specific humoral and cellular immune responses during treatment of adenosine deaminase deficient severe combined immunodeficiency (ADA-SCID) with polyethylene glycol modified bovine adenosine deaminase (PEG-ADA)
72. The use of bovine polyethylene gylcol modified adenosine deaminase (PEG-ADA) in correcting the immunodeficiency in a child with severe combined imunodeficiency-adenosine deaminase deficency (SCID-ADA (−))
73. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol modified adenosine deaminase
74. Development of perfluorochemical emulsion as blood gas carrier
75. FDA questions Fluosol efficacy
76. Soluble dextran-hemoglobin conplex as a potential blood substitute
77. A blood substitute from hydroxyethyl starch and hemoglobin
78. The maintenance of respiration and hemodynamics after complete replacement of blood with artificial oxygen transporters: polyhemoglobinalbumin and polyhemoglobin
79. Modification of human hemoglobin with polyethylene glycol: a new candidate for blood substitute
80. Preparation and evaluation of pyridoxylated-polymerized human hemoglobin
81. Hemoglobin solution from tetramer to polymer
82. Hemoglobin-inulin conjugate as an oxygen carrying blood substitute
83. Morphologic effects following massive exchange tranfusions with a stroma-free hemoglobin solution
84. Preparation and evaluation of hemoglobin-polyethylene glycol conjugate (pyridoxylated polyethylene glycol hemoglobin) as an oxygen carrying resuscitation fluid
85. Synthesis of monomethoxypolyoxyethylene-bound hemoglobins
86. Acylation of human hemoglobin with polyoxyethylene derivatives
87. Physiologic effects of pyridoxylated-hemoglobin-polyethylene glycol conjugate solution in exchange transfusions
88. Hemoglobin pyridoxylation, Optimization and observation of an additional new PLP-Hb species by HPLC resolution
89. Transfusion of polyoxyethylene conjugate of pyridoxylated human hemoglobin in dogs with hemorrhagic shock
90. Use of a new oxygen carying blood substitute
91. In vitro evaluation of a pyridoxylated-hemoglobin-polyoxyethylene conjugate
92. A new resuscitation fluid ‘stabilized hemoglobin’ parameters and characteristics
93. Hemoglobin solutions coupled with polyethylene glycol 1900: preparation, purification quality control and pharmacologic trials by hemorrhagic shock
94. Free radicals and disease in man
95. Superoxide dismutase and pulmonary toxicity
96. Approaches to prevention of asbestos-induced lung diseases using polyethylene glycol (PEG)-conjugated catalase
97. Superoxide radicals in feline intestinal ischemia
98. Oxygen derived free radicals in postischemic tissue injury
99. Orgotein
100. Orgotein: a new drug for the treatment of radiation cystitis
101. Safety and plasma concentrations of bovine superoxide dismuatase administered to human premature infants
102. Orgotein: a new anti-inflammatory metalloprotein drug: preliminary evaluation of clinical efficacy and safety in degenerative joint disease
103. Bovine superoxide dismutase in Fanconi anemia: therapeutic trial in two patients
104. Biological defense mechanisms: the production by leukocytes of superoxide dismutase, a potent bactericidal agent
105. Intérêt de l'équilage en O.R.
106. Effects of free radical scavengers in renal circulation after ischemia in the rabbit
107. Oxygen radicals mediate the cerebral arteriolardilator from arachidonate and bradykinin in cats
108. Effects of superoxide radicals on myoblast growth and differentiation
109. Orgotein: the drug version of bovine Cu,Zn-SOD.I.
110. Protection against oxygen toxicity by intravenous injections of liposome entrapped catalase and superoxide dismutase
111. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase
112. Superoxide dismutase and catalase conjugated to polyethylene glycol increase endothelial enzyme activity and oxidant resistance
113. The effect of oxygen free radicals on the preserved kidney
114. Increased survival of skin flaps by scavengers of superoxide radical
115. Superoxide dismutase conjugated to polyethylene glycol provides sustained protection against myocardial ischemic/reperfusion injury in the canine heart
116. Evidence against the ‘early protection-delayed death’ hypothesis of superoxide dismutase therapy in experimental myocardial infarction
117. Mitigation of pulmonary oxygen toxicity in premature lambs wth intravenous antioxidants
118. Antioxidants and antioxidant enzymes protect against pulmonary oxygen toxicity in the rabbit
119. Inhibition of lung injury inflammation and interstitial pulmonary fibrosis by polyethylene glycol-conjugated catalase in a rapid inhalation model of asbestosis
120. Clinical pharmacokinetics of PEG-superoxide dismutase
121. Perirenal transplant quantification of free radical scavenger enzyme activity (FRSEA)—the effect of a single dose of PEG-SOD and renal failure
122. Failure of antioxidant therapy (polyethylene glycol-conjugated catalase) in acute pancreatitis
123. Evidence for a role of oxygen derived free radicals in the pathogenesis of caerulein-induced actue pancreatitis in rats
124. Polyethylene glycol-attached antioxidant enzymes decrease pulmonary oxygen toxicity in rats
125. Preparation of polyethylene glycol NAD and its application in a model enzyme reactor
126. Oral d-α tocopherol polyethylene glycol-1000 succinate treatment for vitamin E deficiency in chronic childhood cholestasis
127. Chemical modification of recombinant interleukin-2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model
128. A Phase I study including pharmacokinetics of PEG-IL-2 in patients with advanced cancer
129. Physiochemical and biological properties of poly(ethylene glycol) coupled immunoglobulin G
130. A doubleblind study of immunotherapy with chemically modified honeybee venom monomethoxypolyethylene glycol-coupled vs. crude honeybee
131. Juniper, E.F., Roberts, R.S., Tech, M., Kennedy, L.K., O'Conner, J., Syty-Golda M., Dolovich, J. and Hargreave, F.E., Polyethylene glycol modified ragweed pollen extract in rhinoconjunctivitis, J. Allergy Clin. Immunol. 75, 578–585.